Hevolution Foundation published a study in Nature showing that application of GLP-1R agonist semaglutide for 3 months improved physiological function, attenuated hallmarks of aging, modulated nutrient sensors, conserved genetic regulators, and increased NAD+ levels, sirtuin expression, and downregulated IGF-1 in aged mice.
Published
Signal category
Research & Knowledge
Quote
“A new study published online this week in Nature shows very promising data in aged mice indicating that application of GLP-1 drugs (e.g. GLP-1R agonist semaglutide) for 3 months improved physiological function, attenuated hallmarks of ageing and modulated nutrient sensors and conserved genetic regulators of ageing.”
— Lorenz Mayr|Hevolution Foundation team
Company
Hevolution Foundation
Together We Thrive
- Industry
- Non-profit Organizations
- Location
- Riyadh, SA
- Company size
- 69 employees
Founded on the belief that every person has the right to live a longer, healthier life, Hevolution Foundation is a global catalyst, partner, and convener on a mission to drive efforts to extend healthy human lifespan and understand aging processes. With a focus on aging as a treatable process, Hevolution Foundation aims to increase the number of aging-related treatments on the market, compress the timeline of drug development, and increase accessibility to therapeutics that extend a healthy healthspan. A global non-profit organization headquartered in Riyadh with a North American hub, and an annual budget of up to $1 Billion, Hevolution Foundation is the second largest geroscience funder with plans to open offices in other international locations to support a cutting-edge, global ecosystem of talent to propel aging and geroscience research forward and achieve medical breakthroughs to help humanity live healthier, longer.